Author:
Wung Peter K.,Guettier Jean-Marc
Publisher
Springer International Publishing
Reference31 articles.
1. Corr P, Williams D. The pathway from idea to regulatory approval: examples for drug development. In: Lo B, Field MJ, editors. Institute of medicine committee on conflict of interest in medical research, education, and practice. Washington, DC: National Academies Press; 2009. p. 375–83.
2. Woosley RL, Cossman J. Drug development and the FDA’s critical path initiative. Clin Pharmacol Ther. 2007;81:129–33.
3. DiMasi JA, Grabowski HG, Hansen RW. Innovation in the pharmaceutical industry: New estimates of R&D costs. J Health Econ. 2016;47:20–33.
4. Hay M, Thomas DW, Craighead JL, Economides C, Rosenthal J. Clinical development success rates for investigational drugs. Nat Biotechnol. 2014;32(1):40–51.
5. Kola I, Landis J. Can the pharmaceutical industry reduce attrition rates? Nat Rev Drug Discov. 2004;3:711–5.